Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Drug Loss Is Intensifying for Rare Cancers amid Rise of Biotech Developers: JSMO Director
February 5, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- National Geriatrics Center to Kick Off Leqembi Treatment on Feb. 13
January 25, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Scientific Societies Urge Greater Caution for COVID Drug Use in Women of Childbearing Age
November 15, 2023
- Chemotherapy Society Urges Govt to Create Body to Spur Drug Discovery
October 31, 2023
- G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
- Flu Drug Spending Hits 48 Billion Yen in FY2017, NCGM Flags Cost-Effectiveness
October 10, 2023
- NCC Announces “No Placebo Initiative” for Cancer Trials
October 10, 2023
- Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- NIID Researcher Contracts Typhoid Fever
August 21, 2023
- Long COVID Depression Persists among Elderly: NIBIOHN Study
July 26, 2023
- Thai Patients to Join NCC Clinical Studies in “World’s First” Cross-Border DCT Deal
June 29, 2023
- Japan’s NCC, Thailand Agree to Run Virtual Clinical Trials
June 15, 2023
- Japan Syphilis Cases on Track to Hit Record for Third Year in a Row
May 31, 2023
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…